--- title: "Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/277495649.md" description: "Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced the formation of its tenth board session, proposing an eleven-member board with six executive directors, one non-executive director, and four independent non-executive directors, pending shareholder approval at the 2025 AGM. The company plans to re-elect most existing directors while independent director Dong Jiahong will retire. Lou Liguang is proposed as a new independent director to enhance oversight. The stock is rated a Buy with a target price of HK$96.90." datetime: "2026-03-02T15:57:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277495649.md) - [en](https://longbridge.com/en/news/277495649.md) - [zh-HK](https://longbridge.com/zh-HK/news/277495649.md) --- > 支持的语言: [English](https://longbridge.com/en/news/277495649.md) | [繁體中文](https://longbridge.com/zh-HK/news/277495649.md) # Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has issued an update. Jiangsu Hengrui Pharmaceuticals has initiated the formation of its tenth board session, proposing an eleven-member board comprising six executive directors, one non-executive director, and four independent non-executive directors, subject to shareholder approval at the 2025 annual general meeting. The company plans to re-elect most existing directors, including its employee representative director, while maintaining continuity in leadership and corporate governance. Independent non-executive director Dong Jiahong will retire at the conclusion of the AGM and step down from all committee roles, with the board expressing thanks for his service and planning to appoint successors to his committee positions. To strengthen its independent oversight, the company proposes appointing Lou Liguang as a new independent non-executive director for the term of the tenth board session, signaling an orderly transition in its governance structure and sustained focus on regulatory compliance and board renewal. The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page. **More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H** Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong that develops, manufactures, and markets prescription drugs. The group focuses on innovative therapeutics and operates through a board structure comprising executive, non-executive, and independent non-executive directors to oversee its strategic and governance framework. **Average Trading Volume:** 2,705,632 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$426.3B For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page. ### 相关股票 - [Hengrui Pharma (600276.CN)](https://longbridge.com/zh-CN/quote/600276.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md) - [HENGRUI PHARMA (01276.HK)](https://longbridge.com/zh-CN/quote/01276.HK.md) ## 相关资讯与研究 - [Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables](https://longbridge.com/zh-CN/news/278349440.md) - [Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug](https://longbridge.com/zh-CN/news/277870666.md) - [Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials](https://longbridge.com/zh-CN/news/277871128.md) - [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-CN/news/278713493.md) - [BioVersys doses first patient in Phase 2b trial of AlpE for pulmonary tuberculosis](https://longbridge.com/zh-CN/news/278826615.md)